MSI-L/dMMR
|
Small Intestinal Carcinoma
|
MSI-L/dMMR
|
Small Intestinal Carcinoma
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
ipilimumab Sensitive: C3 – Early Trials
|
ipilimumab Sensitive: C3 – Early Trials
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
MSI-L/dMMR
|
CRC
|
MSI-L/dMMR
|
CRC
|
camrelizumab + SHR7390 Sensitive: C3 – Early Trials
|
camrelizumab + SHR7390 Sensitive: C3 – Early Trials
|